Rising Popularity of “Magic” Amanita Mushrooms Sparks Safety Concerns

Rising Popularity of "Magic" Amanita Mushrooms Sparks Safety Concerns

University of California San Diego researchers warn of a troubling trend: a surge in interest in the potentially harmful Amanita muscaria mushroom, often misleadingly marketed as a therapeutic alternative to psilocybin.

Google Searches Skyrocket

A new study published in the American Journal of Preventive Medicine by UC San Diego’s Herbert Wertheim School of Public Health and Human Longevity Science reveals a staggering 114% increase in Google searches for Amanita muscaria from 2022 to 2023. Researchers suggest this rise may be fueled by growing interest in psilocybin’s potential for treating depression.

Similar Effects, Vastly Different Risks

Both Amanita muscaria and psilocybin mushrooms have mind-altering properties. However, the crucial difference lies in their chemical makeup. Amanita muscaria contains muscimol and ibotenic acid, which can be more toxic than fentanyl, cocaine, and PCP, according to the study’s review. Psilocybin, on the other hand, is being studied for its antidepressant effects.

The study raises concerns about misleading marketing practices. Gummies and chocolates containing Amanita muscaria are being sold with claims of treating anxiety and depression, often referencing psilocybin research. This lack of distinction between the two substances violates consumer rights, argues Dr. Eric Leas, the study’s senior author.

Psilocybin vs. Amanita muscaria: Different Mechanisms

Psilocybin works by interacting with serotonin receptors, promoting feelings of happiness and optimism. Amanita muscaria, on the other hand, acts as a depressant similar to alcohol, suppressing the central nervous system. Leas emphasises the importance of informed consent. Consumers have the right to understand the substance they’re taking and its potential risks and benefits.

Regulatory Loopholes

Psilocybin is a Schedule 1 controlled substance, making its use illegal outside of clinical trials. However, Amanita muscaria isn’t currently regulated by the Controlled Substances Act (except in Louisiana). This loophole allows it to be marketed as a dietary supplement, a category with less stringent regulations.

Call for Action

The study authors urge for stricter regulations. The most restrictive option would be adding Amanita muscaria to the Controlled Substances list. Alternatively, they propose commonsense measures like age restrictions, accurate dosing, childproof packaging, and responsible marketing. They also advocate for mental health professionals to educate patients about the differences between psilocybin and Amanita muscaria.

The study underscores the urgency for action. “Companies are pushing the limits,” says Dr. Leas. “Consumers are misled and at risk.” The authors call for a public health response to prevent potential harm from this dangerous lookalike.

Source

Scitechdaily

Leave a Reply

Your email address will not be published.